Shukra Pharmaceuticals Ltd Financials
Company Logo

Shukra Pharmaceuticals Ltd Financial Statement

Shukra Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue6.57
Operating Expense4.89
Net Profit0.54
Net Profit Margin8.22
Earning Per Share0.25
EBIDTA1.64
Effective Tax Rate17.26
Invest in Shukra Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Shukra Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual74.57
Operating Expenses Annual55.17
Operating Profit Annual22.22
Interest Annual0.29
Depreciation2.05
Net Profit Annual18.54
Tax Annual1.35

Shukra Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning3.97
Cash Flow from Operations-5.20
Cash Flow from Investing-1.20
Cash Flow from Financing12.41
Cash Flow at the End9.98

Shukra Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)29.80
PBIT Margin (%)27.05
PBT Margin (%)-66.27
Net PROFIT Margin (%)24.86
Return On Networth / Equity (%)44.71
Return On Networth /Employed (%)44.16
Return On Assets (%)40.53
Total Debt / Equity (X)0.10
Asset Turnover Ratio (%)1.63

Shukra Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual19.94
Total Current Assets Annual56.23
Non Current Assets Annual21.60
Total Shareholders Funds Annual57.64
Total Assets Annual77.84

Shukra Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 22, 2024, Shukra Pharmaceuticals Ltd has a market capitalization of 357.47 Cr. Value Research classifies it as a Small-Cap company.
Yes, Shukra Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.05.
In FY 2023 , Shukra Pharmaceuticals Ltd recorded a total revenue of approximately 74.57 Cr marking a significant milestone in the company's financial performance.
Shukra Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 1.8% and 0.6% annually, respectively..
Shukra Pharmaceuticals Ltd's current PE ratio is 19.28.
Shukra Pharmaceuticals Ltd's ROCE averaged 18.4% from the FY ending March 2022 to 2024, with a median of 15.5%. It peaked at 33.1% in March 2024, reflecting strong capital efficiency over the period..
Shukra Pharmaceuticals Ltd's latest EBIT is Rs. 20.17 Cr, surpassing the average EBIT of Rs. 8.73 Cr over the 5 years..